Pancreatic Cancer Diagnostic Market

Key data points: Market size in 2027 = $3.1 billion and 2035 = $5.2 billion, growth forecast = 7.3% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in pancreatic cancer diagnostic market to 2035 by type (imaging, tumor biomarker, biopsy, and others), application (hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) Pancreatic Cancer Diagnostic Market The future of the global pancreatic cancer diagnostic market looks promising with opportunities in the hospital and clinic markets. The global pancreatic cancer diagnostic market is expected to reach an estimated $5.2 billion by 2035 from $3.1 billion in 2027 with a CAGR of 7.3% from 2027 to 2035. The major drivers for this market are the increasing prevalence of pancreatic cancer, the rising demand for early detection methods, and the growing awareness about cancer diagnostic tools. • Lucintel forecasts that, within the type category, tumor biomarker is expected to witness the highest growth over the forecast period due to more reliance on biomarkers for early cancer detection. • Within the application category, hospitals is expected to witness higher growth over the forecast period due to more cases of pancreatic cancer diagnosed in hospitals. • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to more investment in healthcare and rise in public awareness for cancer screening. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Pancreatic Cancer Diagnostic Market The pancreatic cancer diagnosis market is expected to transition from symptom-based diagnosis to early, marker-based diagnoses by 2027. Clinical VALIDATION of various techniques including liquid biopsy, artificial intelligence (AI), and imaging is ongoing. Risk-based surveillance is also being clinically evaluated. While these innovations have the potential to improve diagnosis and overall survival (OS) of patients with pancreatic cancer, reimbursement will be a key limiting factor. Lucintel expects integrated diagnostic pathways will become the norm. • Risk-based Surveillance: The Consortium for the Advancement of Pathway Diagnosis (CAPS) is focused on individuals who are at-risk, including those with pathogenic variants or a family history of pancreatic cancer. Other high-risk individuals are being monitored with periodic imaging (i.e. annual or every six to twelve months). Improved early diagnosis of pancreatic cancer improves the chances of successful surgical removal. • Liquid Biopsy: Over the last few years, several studies have investigated various biomarkers associated with pancreatic cancer and have evaluated methods to improve cancer screening. It is anticipated that improvements in biomarker panels will reduce the time required to perform cancer screening. • Artificial Intelligence: Pancreatic duct changes and pancreatic cancer are often asymptomatic. Small cancers are often Machine Learning (ML) is being used by radiologists to interpret various scans in an effort to improve the detection of cancers and other abnormalities. There are ongoing studies to evaluate the impact of ML in interpreting various cancers. Improvements in ML will better assist health care practitioners in interpreting various scans, and potentially refer more patients for further evaluation. • Multiparametric Imaging: Integrated use of endoscopic ultrasound (EUS), contrast-enhanced CT, MRI, and PET is expected in the next several years. Tissue sampling with EUS will still be performed if inconclusive findings from the aforementioned studies. Advances in imaging are expected to improve staging confidence and decrease delays prior to therapy. • Companion Diagnostics: Molecular testing of tumors in advanced stage cancers is increasing and so is the use of molecular profiling. Molecular testing is also used to evaluate the presence of alterations that can impact treatment. Recently, molecular profiling was used to evaluate microsatellite instability (MSI) to understand if a tumor is deficient in its mismatch repair system. Soon, diagnostic labs are expected to improve the efficiency in the time it takes to obtain a tissue sample, provide clinically relevant data and meet the needs of the oncologist and the patient. Diagnostics and therapeutics are increasingly integrated. The focus in oncology is shifting from treatment to prevention, but this will take time. In the interim, the field has the opportunity to impact the survival of individuals with high-risk cancers by integrating advancements in diagnostics and molecular pathology. This creates a market opportunity for integration of advanced molecular diagnostics with imaging to support high-risk cancer surveillance. This is expected to occur over the next decade at specialty care centers. Recent Developments in the Pancreatic Cancer Diagnostic Market The market for in vitro diagnostic tests for pancreatic cancer is expected to grow in the 2025-2027 time frame, especially with the emergence of technologies such as liquid biopsies and AI. Lucintel market outlook is positive given the increase in partnerships and the completion of clinical trials. Despite an increase in innovations in this space, reimbursement, and consequently, the adoption of these innovations in the health care market, is lagging. • Liquid Biopsy: Freenome, a liquid biopsy company, announced in January 2025, the expansion of its early cancer detection program to include molecular signals for pancreatic cancer. While the research is moving in the right direction, commercial barriers will continue to exist until these innovations are able to detect these signals for early stage cancers. • Artificial Intelligence (AI). In 2025, the Mayo Clinic and other partners published studies to validate AI in identifying pancreatic tumors. Success in this field will increase the demand for other AI applications in the field of medicine. • Biomarkers. The NCI's Pancreatic Cancer Detection Consortium funded several research studies to identify biomarkers associated with pancreatic cancer in high risk individuals and the general population. Focusing biomarker research on individuals at high risk, such as those with a genetic predisposition or recently diagnosed with diabetes, may improve the overall effect of the research. • Companion-diagnostic Expansion: 2025 saw greater uptake of pancreatic tumor profiling by the precision oncology industry. This was coupled with an expanded use of next-generation sequencing (NGS) panels. As the use of companion diagnostics increases, broadening the field of molecular tumor board discussions, we may expect an increase in the use of molecular tumor tests and the associated revenue from these tests. • Clinical-network Collaboration: The ACS anticipates 67,440 new cases of pancreatic cancer in the U.S. for 2025. These projections stimulate the formation of testing and referral networks by diagnostic and cancer center entities, respectively. Traditionally, pancreatic cancer diagnostics have been geared toward defining the cancer in cases where it is previously unknown. More recently, there has been an effort to develop diagnostics to identify high-risk patients and to select the appropriate therapy. Venture capital has been directed toward innovation in areas such as molecular diagnostics, artificial intelligence pathology, and integrative/multimodal imaging. In the coming years, it is likely that the diagnostics space will see the development of innovative products and the establishment of partnerships among vendors of diagnostics, software, and services. Strategic Growth Opportunities in the Pancreatic Cancer Diagnostic Market The market for in-vitro diagnostics for pancreatic cancer is emerging. The investment trend between 2024 and 2026 is expected to be positive due to increasing late diagnosis and rising oncology expenses. Lucintel’s report anticipates the demand for pancreatic cancer diagnostic tests to increase due to the unavailability of clinically validated pathways, and dec allerkit ed centralized testing. Decentralized testing may increase the scope of pancreatic cancer diagnostic testing beyond tertiary care centers. • Early Detection: In vitro diagnostic tests may be developed to identify pancreatic cancer using liquid biopsy. The American Cancer Society projects that in 2025, approximately 67,440 Americans will be diagnosed with pancreatic cancer. The positive trend in early detection will facilitate the adoption of blood tests within the medical community. It is expected that within the next 5 years, oncology practices will have the facilities to routinely perform liquid biopsy to detect cancer. • Risk Stratified Screening: Individuals at hereditary risk for pancreatic cancer, and individuals with new-onset diabetes or chronic pancreatitis, also represent at-risk populations for whom screening may be warranted. It is anticipated that the volume of metabolic and chronic disorders may increase, and may warrant further diagnostic testing. • Imaging: Certain AI applications within imaging protocols have the potential to standardize and efficiently process a large volume of radiology interpretations and therefore provide a source of recurring revenue for hospitals and imaging groups. The US Food and Drug Administration (FDA) has been expediting the review of AI medical device applications, and by February 2025, the FDA had cleared more than 1,000 AI medical devices. Like other ancillary services, AI applications will transform how imaging studies are processed to assist with triage and determine the next steps. • Decentralized Molecular Testing: Laboratory testing, especially at the point-of-care, allows for rapid evaluation and triage to more sophisticated levels of care. The World Health Organization (WHO) estimated that in March 2025, approximately 4.9 billion individuals did not have access to essential diagnostic tests. Molecular diagnostics and other portable laboratory testing will assist laboratories in extending their service coverage and assist in the development of new sources of revenue. • Companion Diagnostics: The use of a biomarker test to assist in the selection of the appropriate cancer therapy increases the value of each test and assists the diagnostic company in developing a long-term, sustainable relationship with the pharmaceutical company. During April 2025, the US Food and Drug Administration (FDA) published guidance that retained its 2016 oncology companion diagnostic policy. It is important for diagnostic companies to focus on the areas that increase the clinical throughput of the laboratories, assist in maximizing reimbursement potential, and help integrate risk assessment, imaging, and molecular diagnostic testing. These combinations have the potential to positively impact the patient and strengthen the revenue stream of the integrated health care delivery system. Pancreatic Cancer Diagnostic Market Drivers and Challenges The oral protein and peptide drug market is maturing due to a variety of factors including more cases of chronic conditions, changing laws and regulations, and improving technologies and methods of doing business. The development of improved delivery systems may result in the introduction of hitherto unthought of agents in the form of tablets and capsules. Also, oral drug delivery is more convenient and acceptable to patients than parenteral (intravenous) drug delivery. Regulatory barriers, patient acceptance, and cost may restrict the growth of the oral drug delivery market. According to Lucintel, in order for the oral protein and peptide drug market to thrive, greater efforts should be made to develop more convenient, safe and effective oral drug delivery products. The factors responsible for driving this market include : • More Demanding Customers: Customers are willing to pay for better, more convenient therapies for conditions like diabetes and obesity. Improving these conditions may reduce the case load for other conditions and create a more urgent need for better therapies. The International Diabetes Federation (IDF) 2025 report estimates the case load of diabetes at 589.3 million. • Drug-Delivery Technology: New innovations in the field have allowed for better transport of peptides and proteins. In 2025, many research initiatives focused on enhancing the stability of peptides and improving their transport across the intestinal barrier. At that time, most of the progress in the field resulted in improved formulations and bioavailability of biologics. Consequently, several biologics that previously could not be commercialized because of formulation issues, became available. • Product Innovation: The invention of drug delivery technologies has allowed the development of a broad range of biologics in oral formulations. Consequently, therapeutic products previously requiring parenteral administration have been marketed. Furthermore, a growing number of clinical studies have been conducted to evaluate the pharmacy and pharmacology of other biologics for oral formulations. Recently developed products have resulted in the advancement of therapy for previously unmet medical conditions. • Manufacturing Advancements: In 2025, major advances in the field of biologics allowed for increased process control in biologics manufacturing Continued improvements in automation and information technologies are expected to further improve the industry in the next few years. • Recent Changes in Regulations and Infrastructures: Guidelines for assessment of complex biologics have been issued by regulatory agencies. The pharmaceutical industry has invested in development of the required infrastructure for manufacture of proteins and peptides. As of February 2025, international pharma companies have initiated projects for development of therapies for diabetes and obesity. Other resources say that there will be additional development in the pharmaceutical and allied industries to advance the regulatory framework, to enhance the protection and promote the development of recombinant proteins and peptides. The challenges facing this market include: • Constraints in Bioavailability: Bioavailability of peptides and proteins is limiting. In fact, case studies have shown that the absolute bioavailability of some peptides is ≤1%. Numerous studies have focused on improving the absorption of peptides and proteins by the use of absorption enhancers. However, there is a risk of introducing variation in the bioavailability of the peptide under study. Until absorption of proteins and peptides is improved, other, more efficient, methods of introducing biologics to the body will continue to be preferred. • Complicated Development and Reimbursement Issues: The development of oral biologics is complicated, time-consuming, and expensive. The clinical trials of oral biologics are long and expensive. There are reimbursement issues, and oral biologics are likely to be cost-prohibitive with other therapies available. So, oral biologics likely will not be widely available in the next few years, and when they are available, they likely will be for conditions in which there is a great impact on quality of life and for which there are no other therapies of significance. • Risks Related To Regulatory, Safety and Supply-Chain: Challenges related to the absorption of oral formulations of proteins and peptides, and food and drug interaction, make development of oral proteins and peptides extremely difficult. Manufacturing challenges related to safety and the consistency of drug delivery also exist. Packaging is another consideration. Disruptions in the pharmaceutical supply chain continued in November 2025. Shortages of ingredients and supplies continued to strain the pharmaceutical supply chain. However, the lack of sufficient capacity in distribution channels was the most significant bottleneck. It is expected that in the coming years, the most significant disruptions to the pharmaceutical supply chain will be caused by reliance on a small number of ingredients suppliers. This will be particularly true for multi-national pharmaceutical companies. The market for oral protein and peptide drugs is expected to continue to expand. The manufacture and formulation of pharmaceuticals has improved, and aided the development of this area of research. In the coming years, the oral protein and peptide drug market will likely be dominated by those companies that have effectively controlled costs and improved the reliability and bioavailability of pharmaceutical products. List of Pancreatic Cancer Diagnostic Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies pancreatic cancer diagnostic market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pancreatic cancer diagnostic market companies profiled in this report include- • Siemens • GE Healthcare • Roche • Philips Healthcare • Danaher Pancreatic Cancer Diagnostic Market by Segment The study includes a forecast for the global pancreatic cancer diagnostic market by type, application, and region. Pancreatic Cancer Diagnostic Market by Type [Value ($B) from 2019 to 2035]: • Imaging • Tumor Biomarker • Biopsy • Others Pancreatic Cancer Diagnostic Market by Application [Value ($B) from 2019 to 2035]: • Hospitals • Clinics • Others Pancreatic Cancer Diagnostic Market by Region [Value ($B) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Pancreatic Cancer Diagnostic Market There is anticipated growth in the diagnosis of various cancers due to innovations in liquid biopsies, molecular tests, and artificial intelligence (AI) in medicine. As these innovations occur, funding and regulatory agencies will also benefit the field. It is anticipated that between 2025 and 2027, various government agencies will not only provide reimbursement for new diagnostic tests, but also increase the availability and capacity of these tests. Based on a recent report by Lucintel, barriers to the clinical adoption of these tests included integration of the diagnostic procedures into the existing clinical workflow and attainment of reimbursement by regulatory agencies. • United States: The food and drug administration (FDA) and the National Cancer Institute (NCI), continue to evaluate cancer diagnosis molecular tests. NCI has recently increased funding for development of molecular diagnostic tests. The Blood Cancer Detection Early Diagnosis Network aims to develop blood-based tests for various cancers. • China: The Early Diagnosis and Treatment of Cancers program, under the Chinese National Health Commission, also fund research projects aimed at incorporating new technologies in cancer diagnostics and therapies. • Germany: Germany is currently in the final phase of the transition process for in-vitro diagnostic devices (IVDs). Like the other countries of the EU, Germany also needs to fully implement the In-vitro Diagnostic Regulation (IVDR) by May 2026. In the interim, Germany is in the process of implementing IVDs for molecular oncology in university hospitals and cancer centers. Therefore, it is likely that more stringent regulations for molecular diagnostic devices will be established to stimulate the development of in-vitro diagnostic devices for cancer, including pancreatic cancer. • India: Health Sector Funds: India’s Union budget for 2025, allocated ₹99,858 crore to the Health and Family Welfare sector. Improvement in the public health services is expected in the coming years. It is expected that public health services and medical diagnostics, particularly in large cities, will be improved in the next 3 to 5 years. • Japan: Cancer Genomics: In 2025, the Japanese Ministry of Health, Labor and Welfare expanded the Cancer Genomic Medicine Program. More hospitals, around 200, participated in the Program in the same year. Also, insurance companies allowed coverage for genomic testing for cancers. Consequently, the accessibility of cancer genomic testing increased and its quality improved. Features of the Global Pancreatic Cancer Diagnostic Market Market Size Estimates: pancreatic cancer diagnostic market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: pancreatic cancer diagnostic market size by type, application, and region in terms of value ($B). Regional Analysis: pancreatic cancer diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the pancreatic cancer diagnostic market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pancreatic cancer diagnostic market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the pancreatic cancer diagnostic market by type (imaging, tumor biomarker, biopsy, and others), application (hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?